China's demand for Health Care has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, import & export, consumer consumption and capital investment for over two decades. This new study examines China's economic trends, investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical data (2012, 2017 and 2022) and long-term forecasts through 2027 and 2032 are presented. Major producers in China are profiled.China's demand for Health Care will continue to grow at about 11% by 2032
The primary and secondary research is done in China in order to access up-to-date government regulations, market information and industry data. Data were collected from the Chinese government publications, Chinese language newspapers and magazines, industry associations, local governments’ industry bureaus, industry publications, and our in-house databases. Interviews are conducted with Chinese industry experts, university professors, and producers in China. Economic models and quantitative methods are applied in this report to project market demand and industry trends. Metric system is used and values are presented in either Yuan (RMB, current price) and/or US dollars.
Our market research reports provide hard-to-find market data and analyses. Today, China has the largest market in the world. Tremendous fast-growing markets for imports and business opportunities for companies around the world. If you want to expand your business or sell your products in China, our research reports provide the insights and projections into Chinese markets necessary for you to do so.
Table of Contents
I. INTRODUCTION
II. BUSINESS ENVIRONMENT
III. HEALTH CARE INDUSTRY ASSESSMENTS
IV. HEALTH CARE INDUSTRY OUTPUTS AND FORECASTS
V. HEALTH CARE MARKET OUTLOOKS
VI. MARKETING STRATEGIES
VII. HEALTH CARE PRODUCER DIRECTORY
I. INTRODUCTION
II. BUSINESS ENVIRONMENT
III. HEALTH CARE INDUSTRY ASSESSMENTS
IV. HEALTH CARE INDUSTRY OUTPUTS AND FORECASTS
V. HEALTH CARE MARKET OUTLOOKS
I. INTRODUCTION
II. BUSINESS ENVIRONMENT
III. HEALTH CARE INDUSTRY OUTPUTS AND FORECASTS
IV. HEALTH CARE MARKET OUTLOOKS
V. MARKETING STRATEGIES
Executive Summary
Focus on China’s Healthcare for 1.3 Billion People
In the two past decades, the healthcare industry has been growing at a fast pace. It is a tremendous challenge to provide healthcare for 1.3 billion people. The dramatic expansions of the healthcare system, drug manufacturing, and health insurance have transformed China’s society and economy. Life expectancy reached 76.8 for women and 72.5 for men now comparing to 69.9 for women and 66.9 for men in 1990. Demographic transition from high mortality to low mortality has helped increase life expectancy. Primary diseases have also shifted from infectious to chronic. Cancer, heart diseases and cerebrovascular diseases are now top killers. Spending on healthcare counts for over 5% of GDP now and continue to increase in the next decade.
Healthcare reform has been one of the key topics on the government agenda in China. Due to the rise in the cost of healthcare, more than 10% of the income is spent on healthcare, which is greater than that spent on education and transportation. The rise in the cost in healthcare would definitely have an outcome of the high cost of the drugs.
There are approximately 4,500 pharmaceutical companies in China, the majority of which are small players with limited local market reach. Rapid consolidation between medium and large players in the sector is anticipated since the Chinese government has been encouraging industry consolidation with an effort to regulate the industry and to better control the pricing of drugs.
China is one of the world’s major producers of pharmaceuticals. Far outpacing other economies in the world, China is the world’s fastest growing pharmaceutical market. Although China has enjoyed the benefits of an expanding market for pharmaceutical production and distribution, the industry is suffering from minimal innovation and investment in R&D and new product development. The sector’s economies of scale have yet to be achieved. Most domestic manufacturers in the pharmaceutical industry lack the autonomic intellectual property and financial resources to develop their own brand name products. Most manufacturers rely on the repetitive production of Chinese medicine, low value-added bulk pharmaceuticals or generic drugs.
Biotechnology is a rapidly growing sector in China. Both production and demand have witnessed significant surges in recent years. China will continue to remain a large importer for biotechnology pharmaceuticals to meet the growing domestic demand. Major imports include biotechnology vaccines, CSF, r-EPO, recombinant human insulin, recombinant human growth hormones, recombinant interferon, and other biotechnology pharmaceuticals.
The health care insurance industry of China includes two main parts such as the social healthcare insurance controlled by the government and commercial healthcare insurance provided by private companies. At present, the social healthcare insurance is under reforms to control the increasing healthcare costs. The development of commercial healthcare insurance in China is not inadequate. But the commercial healthcare insurance market has a great growth potential. Today, China has the largest healthcare market in the world. The Chinese healthcare industry is one of the fastest-growing sectors in China, growing at double digit rate each year. Tremendous fast-growing markets for imports and business opportunities for companies around the world.
Focus on China’s Healthcare for 1.3 Billion People
In the two past decades, the healthcare industry has been growing at a fast pace. It is a tremendous challenge to provide healthcare for 1.3 billion people. The dramatic expansions of the healthcare system, drug manufacturing, and health insurance have transformed China’s society and economy. Life expectancy reached 76.8 for women and 72.5 for men now comparing to 69.9 for women and 66.9 for men in 1990. Demographic transition from high mortality to low mortality has helped increase life expectancy. Primary diseases have also shifted from infectious to chronic. Cancer, heart diseases and cerebrovascular diseases are now top killers. Spending on healthcare counts for over 5% of GDP now and continue to increase in the next decade.
Healthcare reform has been one of the key topics on the government agenda in China. Due to the rise in the cost of healthcare, more than 10% of the income is spent on healthcare, which is greater than that spent on education and transportation. The rise in the cost in healthcare would definitely have an outcome of the high cost of the drugs.
There are approximately 4,500 pharmaceutical companies in China, the majority of which are small players with limited local market reach. Rapid consolidation between medium and large players in the sector is anticipated since the Chinese government has been encouraging industry consolidation with an effort to regulate the industry and to better control the pricing of drugs.
China is one of the world’s major producers of pharmaceuticals. Far outpacing other economies in the world, China is the world’s fastest growing pharmaceutical market. Although China has enjoyed the benefits of an expanding market for pharmaceutical production and distribution, the industry is suffering from minimal innovation and investment in R&D and new product development. The sector’s economies of scale have yet to be achieved. Most domestic manufacturers in the pharmaceutical industry lack the autonomic intellectual property and financial resources to develop their own brand name products. Most manufacturers rely on the repetitive production of Chinese medicine, low value-added bulk pharmaceuticals or generic drugs.
Biotechnology is a rapidly growing sector in China. Both production and demand have witnessed significant surges in recent years. China will continue to remain a large importer for biotechnology pharmaceuticals to meet the growing domestic demand. Major imports include biotechnology vaccines, CSF, r-EPO, recombinant human insulin, recombinant human growth hormones, recombinant interferon, and other biotechnology pharmaceuticals.
The health care insurance industry of China includes two main parts such as the social healthcare insurance controlled by the government and commercial healthcare insurance provided by private companies. At present, the social healthcare insurance is under reforms to control the increasing healthcare costs. The development of commercial healthcare insurance in China is not inadequate. But the commercial healthcare insurance market has a great growth potential. Today, China has the largest healthcare market in the world. The Chinese healthcare industry is one of the fastest-growing sectors in China, growing at double digit rate each year. Tremendous fast-growing markets for imports and business opportunities for companies around the world.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Huabei Pharmaceutical Group Co., Ltd.
- Shijiazhuang Pharmaceutical Group Co., Ltd.
